Ventricular remodeling in heart failure: a credible surrogate endpoint.
暂无分享,去创建一个
J. Cohn | M. Konstam | J. Udelson | I. Anand
[1] R M Whitlock,et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.
[2] J. B. Garrison,et al. Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography. , 1979, The New England journal of medicine.
[3] J. Berlin,et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. , 2001, American heart journal.
[4] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[5] B. Bozkurt,et al. Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.
[6] M. Pfeffer,et al. Ventricular enlargement and reduced survival after myocardial infarction. , 1987, Circulation.
[7] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[8] M. Kinoshita,et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[9] J. Cohn,et al. Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.
[10] L. Fisher,et al. Surrogate end points in heart failure. , 2002, Journal of the American College of Cardiology.
[11] S. Yusuf,et al. Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.
[12] G. Gamble,et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition , 1991, The Lancet.
[13] M. Horie,et al. Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction , 2003, Circulation.
[14] R. McKelvie,et al. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. , 2000, Circulation.
[15] W Grossman,et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. , 1986, Circulation.
[16] T. Lüscher,et al. Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure , 2000 .
[17] J. Weiss,et al. Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. , 1982, The American journal of cardiology.
[18] M. Kronenberg,et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. , 1993, Circulation.
[19] M. Quiñones,et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. , 1995, Circulation.
[20] David P Miller,et al. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. , 1997, Circulation.
[21] G. Lamas,et al. Quantitative Two-Dimensional Echocardiographic Measurements are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction: The Protective Effect of Captopril , 1994, Circulation.
[22] M. Konstam,et al. Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure? , 1999 .
[23] S. Yusuf,et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.
[24] R. Califf,et al. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) , 2002, Circulation.
[25] P. Grayburn,et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.
[26] J. Cohn,et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.
[27] Sebastian Philipp,et al. Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ETA) Receptor Blockade in Chronic Heart Failure: The Heart Failure ETA Receptor Blockade Trial (HEAT) , 2002, Circulation.
[28] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[29] K. Hammermeister,et al. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. , 1979, Circulation.
[30] K. Hammermeister,et al. Variables Predictive of Survival in Patients with Coronary Disease: Selection by Univariate and Multivariate Analyses from the Clinical, Electrocardiographic, Exercise, Arteriographic, and Quantitative Angiographic Evaluations , 1979 .
[31] R. Doughty,et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease , 1997 .
[32] J. McMurray,et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[33] J. Cohn,et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.
[34] W. Rand,et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. , 2000, American heart journal.
[35] L. Fisher,et al. Relation between changes in ejection fraction over time and subsequent mortality and morbidity in Val-HeFT , 2003 .
[36] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.
[37] C. Benedict,et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. , 1994, The American journal of cardiology.